GPCR - NASDAQ
Structure Therapeutics Inc.
$37.50
-2.7%Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotStructure Therapeutics Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Structure Therapeutics Inc. Cash Flow Statement
GPCR • NASDAQ
| Structure Therapeutics Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-141.2M | -122.5M | -89.6M | -51.3M | -38M | -15.9M | |
1.3M | 992K | 295K | 277K | 72K | 0.0 | |
29M | 18.8M | 8.2M | 2.5M | 1.5M | 570K | |
-23M | -16.9M | -5.3M | -558K | 268K | 77K | |
-88.3M | 3M | 7M | 3M | 4.1M | 946K | |
-222.2M | -116.6M | -79.5M | -46.1M | -32.2M | -14.3M | |
INVESTING ACTIVITIES | ||||||
-3.6M | -1.3M | -2.2M | -155K | -1.2M | -19K | |
-547.4M | -702.5M | -417M | -123.5M | -4.2M | -21.1M | |
630.5M | 344.9M | 151M | 61.5M | 23.3M | 0.0 | |
10.2M | 0.0 | -231.4K | 0.0 | 0.0 | 0.0 | |
(89.8M) | -358.9M | -268.3M | -62.1M | (17.9M) | -21.1M | |
FINANCING ACTIVITIES | ||||||
767.2M | 514.6M | 472.3M | 0.0 | 0.0 | 0.0 | |
-4.7M | 690K | -20.8M | -2.5M | -104K | 0.0 | |
762.5M | 515.3M | 451.5M | 29M | 103.3M | 25.8M | |
CASH FLOW SUMMARY | ||||||
-1.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
630.1M | 39.7M | 103.7M | -79.2M | 89M | -9.6M | |
169.5M | 129.8M | 26.1M | 105.3M | 16.4M | 25.9M | |
799.6M | 169.5M | 129.8M | 26.1M | 105.3M | 16.4M | |
-225.8M | -117.9M | -81.7M | -46.3M | -33.4M | -14.3M |
SEC Filings
GPCR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 15, 2026 | April 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 05, 2026 | December 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 10, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 |
Related Guides
Continue your GPCR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.